ARTICLE | Company News
Aduro BioTech Inc. (NASDAQ:ADRO) revealed in an SEC filing that the Janssen Biotech Inc. subsidiary of Johnson & Johnson (NYSE:JNJ) will terminate its licenses for three cancer therapies, effective Dec. 24. A Janssen spokesperson told BioCentury its decision was based on preclinical and clinical data that do not support further development by the company.
Janssen gained exclusive, worldwide rights in 2014 to ADU-214, ADU-741 and GVAX Prostate (see "Aduro Biotech, J&J Deal")...